AstraZeneca PT receives Investment Bank Analyst Rating Update
- ByInvesting.com-
Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| BATS Europe | GBP | Delayed | ||
| BATS Europe | SEK | Delayed | ||
| NASDAQ | USD | Real-time | ||
| OTC Markets | USD | Delayed | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
By Scott Kanowsky Investing.com -- Shares in CinCor Pharma Inc (NASDAQ:CINC) surged by more than 133% in pre-market trading on Monday after AstraZeneca PLC (LON:AZN) agreed to...
By Peter Nurse Investing.com - European stock markets edged higher Monday, with sentiment boosted by China’s decision to fully reopen its borders as well as stronger-than-expected...
Treasury yields rise again, weighing on stocks Oil trading above $90 US dollar flat Key EventsFutures on the Dow Jones, S&P 500, NASDAQ and Russell 2000 wavered in trading on...
One of the best ways to safeguard investments is by parking money in the healthcare sector. This is because demand for healthcare services does not change with market conditions....
Falling Covid-19 prevalence and widespread vaccinations have boosted confidence in the durability of the recovery. Several data points are at post-pandemic highs and that suggests...
AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Sell | Sell | Buy |
| Technical Indicators | Strong Buy | Buy | Strong Sell | Strong Sell | Strong Buy |
| Summary | Strong Buy | Neutral | Strong Sell | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 160.27 | 161.42 | 154.76 | +15.84 | +10.97% | 232.88M | NASDAQ | |||
| 93.45 | 94.28 | 92.64 | +1.04 | +1.13% | 14.32M | NYSE | |||
| 143.96 | 144.25 | 141.90 | +2.10 | +1.48% | 53.60M | NASDAQ | |||
| 224.71 | 227.08 | 223.67 | -0.19 | -0.08% | 6.72M | NYSE | |||
| 9.00 | 9.38 | 8.62 | +0.13 | +1.47% | 26.13M | NASDAQ | |||
| 127.53 | 128.99 | 126.01 | +0.71 | +0.56% | 5.83M | NYSE | |||
| 141.15 | 141.74 | 140.74 | -0.57 | -0.40% | 5.39M | NYSE | |||
| 99.22 | 99.49 | 96.92 | +2.04 | +2.10% | 67.87M | NASDAQ | |||
| 198.02 | 201.66 | 192.78 | +4.79 | +2.48% | 48.45M | NASDAQ | |||
| 36.50 | 36.56 | 35.99 | +0.22 | +0.61% | 4.27M | NASDAQ | |||
| 5.63 | 5.77 | 5.42 | -0.090 | -1.57% | 197.30K | NASDAQ | |||
| 52.58 | 55.62 | 51.45 | +0.43 | +0.82% | 8.29M | NASDAQ | |||
| 32.69 | 32.94 | 32.24 | -0.22 | -0.67% | 47.38K | NYSE | |||
| 20.01 | 21.17 | 19.38 | -0.22 | -1.09% | 3.49M | NYSE | |||
| 95.69 | 96.47 | 89.62 | +6.37 | +7.13% | 102.32K | NASDAQ |